1 January 2016 in Journal of Korean Medical Science
Xiang J, et al. J Korean Med Sci. 2016 May;31(5):688-694. https://doi.org/10.3346/jkms.2016.31.5.688
1 April 2019 in Neuropsychiatric Disease and Treatment
Introduction: Recently, molecular epidemiological studies have suggested that aldehyde dehydrogenase 2 (ALDH2) rs671 G>A polymorphism may be a risk factor for ischemic stroke (IS). However, the results reported have not been consistent. Methods: We conducted the meta-analysis to explore the precise association between ALDH2 rs671 G>A polymorphism and IS risk. Five online databases were searched and the relative studies were reviewed from inception to October 1, 2018. Odds ratios (ORs) and corresponding 95% confidence intervals (CIs) were calculated in each genetic model of the general and subgroup. Furthermore, the heterogeneity, accumulative analyses, sensitivity analyses and publication bias were calculated simultaneously. Results: Overall, nine case-control studies involving 6,129 subjects were included in this meta-analysis. All studies were focused on the Chinese population and some significant associations were found between ALDH2 rs671 G>A polymorphism and IS risk (A vs G: OR=1.29, 95% CI=1.01–1.65, P=0.04, I2=78.2%; AA vs GG: OR=1.86, 95% CI=1.27–2.21, P<0.01, I2=11.3%; AA vs GG + GA: OR=1.67, 95% CI=1.27–2.19, PA polymorphism may play an important role in the occurrence of IS by reducing the activity of ALDH2 and interfering with the metabolic processes involving acetaldehyde.